TrialBreast cancer research and treatment2012

Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.

B Ramaswamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.